HB2307 amends Virginia’s Prescription Monitoring Program (PMP) laws and pharmacy technician registration rules. On the PMP side, it keeps the existing requirement that prescribers register with the program and expands when they must query it before prescribing certain controlled substances. For the period before July 1, 2027, prescribers must check the PMP when starting a new course of opioid treatment expected to last more than seven consecutive days, and before issuing a written certification for cannabis oil. Beginning July 1, 2027, the bill shifts the trigger to benzodiazepines or opiates expected to last more than 90 consecutive days, while preserving the requirement for opioid use disorder treatment agreements and cannabis oil certifications.
The bill also creates and clarifies several exceptions to PMP-check requirements. It exempts certain settings and conditions such as hospice or palliative care, inpatient hospital admission or discharge, nursing home or assisted living care using a sole-source pharmacy, sickle cell pain management, and temporary PMP outages or emergency access failures. For the later effective date, it also authorizes the Secretary of Health and Human Resources to publish a list of low-abuse benzodiazepines or opiates that would not trigger the PMP-check requirement, and it adds exemptions for pain management related to dialysis and cancer treatment.
A second major part of the bill revises pharmacy technician law. It expands the list of tasks registered pharmacy technicians may perform, including prescription entry, labeling, inventory handling, refill authorization for certain drugs, and, under supervision, administration of certain vaccines to persons age three and older. It also sets out training and certification requirements for registration, creates rules for pharmacy technician trainees and interns, provides limited-use registrations for technicians working exclusively in free clinic pharmacies, and allows certain nurses at opioid treatment program pharmacies to perform technician duties with pharmacist verification of take-home doses.
The bill’s impact on state law is to tighten and modernize controlled-substance monitoring while also broadening the pharmacy workforce’s authorized functions. It affects prescribers, pharmacists, pharmacy technicians, trainees, interns, free clinic pharmacies, opioid treatment programs, and patients receiving opioids, benzodiazepines, cannabis oil certifications, or treatment for conditions such as cancer, dialysis-related pain, and sickle cell disease. It also creates a phased implementation, with one set of PMP rules effective immediately and a broader set taking effect in 2027.
The overall sentiment appears strongly favorable and noncontroversial. The bill advanced unanimously through subcommittee, committee, and both chambers, with no recorded nay votes in the provided history. The main policy tension reflected in the text is between stronger monitoring of controlled-substance prescribing and preserving access and administrative flexibility for legitimate care settings, especially hospice, inpatient care, free clinics, opioid treatment programs, and patients with serious or chronic pain conditions.
HB2307 amends Virginia Code §§ 54.1-2522.1 and 54.1-3321. It changes when prescribers must query the Prescription Monitoring Program, adds and refines exemptions from that duty, and establishes a later-effective-date standard for benzodiazepines and opiates. It also expands pharmacy technician registration, training, and scope-of-practice rules, including limited-use registrations for free clinic pharmacies, trainee registration, and certain vaccine administration authority under pharmacist supervision.
The bill appears to have broad bipartisan support and little visible opposition. It passed subcommittee, full committee, the House, and the Senate unanimously in the provided votes. The discussion record provided does not include transcript debate, but the vote pattern suggests the bill was viewed as a practical update to prescribing oversight and pharmacy staffing rules rather than a controversial policy change.
No major opposition is reflected in the available record. The only notable policy balancing point is that the bill increases PMP-check requirements for prescribers while carving out numerous exceptions for hospice, palliative care, inpatient and discharge settings, nursing homes, assisted living facilities with sole-source pharmacies, sickle cell pain management, dialysis, cancer treatment, and low-abuse medications identified by the Secretary of Health and Human Resources. On the pharmacy side, the bill’s expanded technician duties and training requirements are paired with limited-use registrations and grandfathering provisions to reduce disruption for existing workers and free clinic pharmacies.